One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 175,000 shares of Roche Holding AG (NYSEARCA: RHHBY) on Thursday, as the share price of this fund traded down nearly 2% in the day’s session. However, the fund’s share price has greatly improved over the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 177,900 shares of Roche. At Thursday’s closing price, this would have valued this sale at roughly $9.0 million. This is only a small fraction of the total holdings. This fund is up 26% over the past 52 weeks.
Here is a quick look at all the other sales that took place across all ARK ETFs:
Fund | Ticker | Company | Shares |
---|---|---|---|
ARKF | 1833HK | Ping An Healthcare and Technology | 524,000 |
ARKG | RHHBY | Roche | 177,900 |
ARKG | SRPT | Sarepta Therapeutics | 17,408 |
ARKG | PSTI | Pluristem Therapeutics | 7,224 |
ARKK | MCRB | Seres Therapeutics | 10,974 |
ARKK | NSTG | Nanostring Technologies | 47,361 |
ARKK | DOCU | Docsign | 51,743 |
ARKK | SQ | Square | 41,400 |
ARKQ | XONE | Exone | 59,797 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
24/7 Wall St.
5 Red-Hot Gaming Stocks to Buy Now With the NFL Betting Season Right Around the Corner
5 Red-Hot Gaming Stocks to Buy Now With the NFL Betting Season Right Around the Corner
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.